B型壁内血肿的自然病史及胸主动脉腔内修复的影响:需谨慎
该研究前瞻性随访40例无局限性内膜破损的B型壁内血肿患者,均先接受优化药物治疗并在5-7天内复查CT。早期TEVAR组并发症率显著高于慢性期TEVAR组(78% vs 38%,P=.003),早期与晚期TEVAR组5年生存率分别为100%和64.9%。
要点
- 无局限性内膜破损的B型壁内血肿可先优化药物治疗并短期复查CT。
- 早期TEVAR并发症率显著高于慢性期TEVAR,需优化手术时机。
- 部分患者单纯药物治疗可完全吸收,避免不必要的早期干预。
核心结论
- B型壁内血肿患者采用优化药物治疗和TEVAR可获得良好结局,但急性期TEVAR并发症风险较高,应优化时机并调整支架设计。
研究设计与样本
- 单中心前瞻性队列研究,自2001年起纳入40例初始CT无局限性内膜破损的B型壁内血肿患者,随访于专门主动脉门诊。
主要发现
- 早期TEVAR组并发症率78%,显著高于慢性期TEVAR组的38%(P=.003)。
- 早期TEVAR组5年生存率100%,晚期TEVAR组64.9%。
关键数值与推荐
- 初始CT无局限性内膜破损的B型壁内血肿患者均先接受优化血压管理、疼痛控制和5-7天内复查CT。
- 住院期间TEVAR指征为新发局限性内膜破损伴血肿厚度进展或持续症状。
临床怎么用
- 对无局限性内膜破损的B型壁内血肿,可先优化药物治疗并短期复查CT,避免急性期常规TEVAR。
- TEVAR时机应个体化,急性期手术需警惕高并发症风险,支架设计需适应壁内血肿病理生理。
局限性
- 单中心回顾性分析,样本量40例,随访时间跨度大,TEVAR时机非随机分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Intramural hematoma (IMH) is characterized by an unpredictable natural history. Thoracic endovascular aortic repair (TEVAR) has increasingly been employed as treatment with limited midterm outcomes reported. METHODS: To better characterize the natural history of type B IMH and TEVAR outcomes, we reviewed our institutional experience. Data were collected prospectively, and patients followed in a dedicated aortic clinic. RESULTS: Since 2001, 40 patients were treated for type B IMH without focal intimal disruption (FID) on initial computed tomography (CT). All patients were initially treated with optimal blood pressure management, pain control, and control CT within 5 to 7 days. Fourteen patients had TEVAR during the index hospitalization due to the presence of a new FID with progression of the IMH thickness or persistent symptoms. Of the remaining 26 patients, 16 required late TEVAR at a mean of 41.3 ± 112.2 months for type B dissection, new FID, or pseudoaneurysm formation. The remaining 10 patients had complete resolution of the IMH on optimal medical therapy (OMT) alone. Patients in the early TEVAR group developed a significantly higher rate of complication than patients treated in the chronic TEVAR phase (78% vs 38%; P = .003). Patients treated with early and late TEVAR had a 5-year survival of 100% and 64.9%, respectively.Clinical ImpactFavorable outcomes can be achieved with OMT and TEVAR for patients with type B IMH. The TEVAR performed in the acute setting carries a substantial risk of complications, emphasizing the need to optimize the timing of TEVAR and adapt stent-graft design to the pathophysiology of IMH.
引用
- Laurin C, Chassé P, Santoire W, et al. Natural History and Impact of Thoracic Endovascular Stent-Grafting on Type B Intramural Hematoma: A World of Caution. J Endovasc Ther. 2026. PMID: 42366687. doi:10.1177/15266028261458174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。